{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:23:53Z","timestamp":1790936633037,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jpsychires.2007.09.001","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T04:29:18Z","timestamp":1212553758000},"page":"894-901","source":"Crossref","is-referenced-by-count":30,"title":["Hypersensitivity of 5-HT2 receptors in OCD patients"],"prefix":"10.1016","volume":"42","author":[{"given":"Aart S.","family":"de Leeuw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman G.M.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2007.09.001_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-002-1057-7","article-title":"Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms","volume":"162","author":"Abi-Saab","year":"2002","journal-title":"Psychopharmacology (Berlin)"},{"issue":"3","key":"10.1016\/j.jpsychires.2007.09.001_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S1461145705005055","article-title":"Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei","volume":"8","author":"Adams","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib3","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th revised ed. Washington, DC: American Psychiatric Press; 1994."},{"key":"10.1016\/j.jpsychires.2007.09.001_bib4","first-page":"72","article-title":"Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats","volume":"250","author":"Bagdy","year":"1989","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/archpsyc.1990.01810210041006","article-title":"Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder","volume":"47","author":"Bastani","year":"1990","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib6","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/00001756-199511000-00013","article-title":"The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain","volume":"6","author":"Baumann","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002130050215","article-title":"Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment","volume":"130","author":"Broocks","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00215473","article-title":"Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects","volume":"92","author":"Charney","year":"1987","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archpsyc.1988.01800260095012","article-title":"Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects","volume":"45","author":"Charney","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0893-133X(98)00070-0","article-title":"Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain","volume":"20","author":"Eriksson","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0893-133X(00)00178-0","article-title":"Low versus standard dose mCPP challenge in obsessive-compulsive patients","volume":"24","author":"Erzegovesi","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2004-827175","article-title":"Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile","volume":"37","author":"Feuchtl","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000123142","article-title":"Serotonergic stimulation of pituitary-adrenocortical function in rats","volume":"32","author":"Fuller","year":"1981","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0024-3205(03)00422-3","article-title":"Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety","volume":"73","author":"Gatch","year":"2003","journal-title":"Life Sciences"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004714-199808000-00007","article-title":"Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers","volume":"18","author":"Gijsman","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0006-3223(94)00235-U","article-title":"m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation","volume":"38","author":"Goodman","year":"1995","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0006-3223(89)90217-5","article-title":"1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain","volume":"25","author":"Hamik","year":"1989","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0028-3908(01)00166-6","article-title":"Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis","volume":"42","author":"Hemrick-Luecke","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-1781(92)90041-Z","article-title":"Fenfluramine stimulation of prolactin in obsessive-compulsive disorder","volume":"42","author":"Hewlett","year":"1992","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.1992.01820010021003","article-title":"Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers","volume":"49","author":"Hollander","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0006-3223(93)90186-H","article-title":"Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD","volume":"34","author":"Hollander","year":"1993","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0006-3223(97)00458-7","article-title":"Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls","volume":"44","author":"Ho Pian","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10799898809048978","article-title":"Functional correlates of serotonin 5-HT1 recognition sites","volume":"8","author":"Hoyer","year":"1988","journal-title":"Journal of Receptor Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0006-3223(91)90184-N","article-title":"m-Chlorophenylpiperazine as a probe of serotonin function","volume":"30","author":"Kahn","year":"1991","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0165-1781(88)90163-1","article-title":"Behavioral indications for serotonin receptor hypersensitivity in panic disorder","volume":"25","author":"Kahn","year":"1988","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-1781(90)90073-E","article-title":"Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects","volume":"33","author":"Kahn","year":"1990","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0306-4530(00)00048-2","article-title":"Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder","volume":"26","author":"Khanna","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1192\/bjp.161.4.517","article-title":"Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls","volume":"161","author":"Lucey","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0006-3223(92)90004-J","article-title":"Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder","volume":"31","author":"McBride","year":"1992","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib31","series-title":"Manual for the profile of mood states","author":"McNair","year":"1971"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-61-6-1179","article-title":"Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans","volume":"61","author":"Mueller","year":"1985","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF00174380","article-title":"Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans","volume":"89","author":"Mueller","year":"1986","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00444705","article-title":"Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers","volume":"98","author":"Murphy","year":"1989","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0006-3223(93)90272-F","article-title":"A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP","volume":"33","author":"Pigott","year":"1993","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0091-3057(01)00669-4","article-title":"Serotonin releasing agents. Neurochemical, therapeutic and adverse effects","volume":"71","author":"Rothman","year":"2002","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-1781(91)90013-F","article-title":"Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects","volume":"38","author":"Seibyl","year":"1991","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0006-3223(94)90628-9","article-title":"The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers","volume":"36","author":"Silverstone","year":"1994","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-8981(80)90183-7","article-title":"The determination of cortisol in human plasma: evaluation and comparison of seven assays","volume":"100","author":"Thijssen","year":"1980","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2005.10.075","article-title":"Desensitization of 5-HT(2A) receptor function by chronic administration of selective serotonin reuptake inhibitors","volume":"1067","author":"Yamauchi","year":"2006","journal-title":"Brain Research"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib42","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1523\/JNEUROSCI.22-21-09635.2002","article-title":"Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (\u2212)DOI","volume":"22","author":"Zhang","year":"2002","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.jpsychires.2007.09.001_bib43","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archpsyc.1987.01800230026006","article-title":"Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls","volume":"44","author":"Zohar","year":"1987","journal-title":"Archives of General Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239560700146X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239560700146X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T17:48:07Z","timestamp":1557596887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239560700146X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S002239560700146X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2007.09.001","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}